In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a ...

China is deepening its regulatory reforms of drugs and devices to foster a globally competitive innovation ecosystem to ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in ...

Atara Biotherapeutics Inc. received a complete response letter from the U.S. FDA for its lead product Ebvallo (tabelecleucel), a breakthrough therapy for Epstein-Barr virus positive post-transplant ...

The EMA recommended the highest number of approvals in the last 15 years in 2024, giving the nod to 114 drugs. That is amongst the highest number in the 30 years of the agency’s existence, said ...

TC Biopharm (Holdings) plc intends to begin proof-of-concept preclinical studies for its lead therapeutic TCB-008, to treat H5N1, or bird flu. TCB-008 is an allogeneic, unmodified cell therapy ...

Hinge Bio Inc. has closed a $30 series A financing to support progression of its lead product candidate, HB-2198, into the clinic for systemic lupus erythematosus (SLE).

At least half of women experience urinary incontinence at some point in their lives but few discuss the condition with their physicians. In part, that’s because most women believe few effective ...

Silexion Therapeutics Corp. has released new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of ...

Oxford Drug Design Ltd. has announced additional in vivo validation for its novel approach against cancer. The innovative approach, using generative AI capabilities, is based on the novel target ...